Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.
We monitored serum p53 antibody (s-p53-Ab) titers in a 76-year-old man with esophageal adenocarcinoma, clinical stage III (T2N2M0), for over 4 years, including during the perioperative period and throughout follow-up after surgery. Screening tests for CA19-9 (205 IU/ml) and s-p53-Abs (381 U/ml) were positive before treatment. After neoadjuvant chemotherapy with 5-FU and cisplatin, CA19-9 decreased to the normal range, but the s-p53-Ab titer remained positive (224 U/ml). Pathological findings of surgically resected specimens showed stage T1b disease and no lymph node metastases. After surgery, s-p53-Ab titers consistently decreased, with no disease recurrence. Although the s-p53-Ab titer remained positive even after 4 years, it decreased to 8.66, 3.59, 2.38, and 1.92 U/ml, 1, 2, 3, and 4 years after surgery, respectively. Thus, monitoring perioperative changes in s-p53-Ab titers proved useful for detecting the presence of residual cancer cells in a patient with superficial esophageal adenocarcinoma.
Department of Surgery, School of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan, hideaki.shimada@med.toho-u.ac.jp.
Hideaki
H
Shimada
Matsuo
M
Nagata
Akihiro
A
Cho
Nobuhiro
N
Takiguchi
Osamu
O
Kainuma
Hiroaki
H
Soda
Atsushi
A
Ikeda
Yoshihiro
Y
Nabeya
Satoshi
S
Yajima
Hiroshi
H
Yamamoto
Takahiro
T
Sugiyama
Makiko
M
Itami
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000628:therapy*; D000368:Aged; D000906:Antibodies / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D013505:Digestive System Surgical Procedures; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D013997:Time Factors; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D000906:Antibodies; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin; D005472:Fluorouracil